POSTMORTEM STUDIES SHED LIGHT ON WHY GBM IS SO FATAL
Northwestern Medicine neuropathologist Craig Horbinski, MD, PhD, shares surprising results from a recent study published in Neuro-Oncology on a collection of postmortem glioblastomas (GBM). Dr. Horbinski also discusses the significant implications the findings have for future research and therapeutics aimed at further improving patient survival.
POSTMORTEM STUDIES SHED LIGHT ON WHY GBM IS SO FATAL
Northwestern Medicine neuropathologist Craig Horbinski, MD, PhD, shares surprising results from a recent study published in Neuro-Oncology on a collection of postmortem glioblastomas (GBM). Dr. Horbinski also discusses the significant implications the findings have for future research and therapeutics aimed at further improving patient survival.
IMMUNOTHERAEUTIC APPROACHES FOR TREATMENT OF GLIOBLASTOMA
A member of the Robert H. Lurie Comprehensive Cancer Center, which was recently awarded an $11.5 million Specialized Program of Research Excellence (SPORE) grant, Rimas Lukas, MD, discusses immunotherapeutic approaches for the treatment of high-grade gliomas. In this video, Dr. Lukas shares results of a promising Phase 1 clinical trial and other projects underway.
IMMUNOTHERAEUTIC APPROACHES FOR TREATMENT OF GLIOBLASTOMA
A member of the Robert H. Lurie Comprehensive Cancer Center, which was recently awarded an $11.5 million Specialized Program of Research Excellence (SPORE) grant, Rimas Lukas, MD, discusses immunotherapeutic approaches for the treatment of high-grade gliomas. In this video, Dr. Lukas shares results of a promising Phase 1 clinical trial and other projects underway.